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Myocardial infarctionTesticular cancer is the most common solid tumor among young men. Regimens containing cisplatin and
bleomycin in combination with etoposide are used for treatment of non-seminomatous germ cell testicular tu-
mors. Cancer patients are at increased risk of thrombosis. Epidemiological studies have identiﬁed chemotherapy
as an additional risk factor for a hypercoagulability state and thrombosis. The risk is more pronounced with
cisplatin-containing chemotherapy. Thromboprophylaxis with LMWH during chemotherapy has demonstrated
to give substantial risk reduction of thromboembolic events. We present a case of acute myocardial infraction
during combined chemotherapy with bleomycin, etoposide and cisplatin for testicular cancer under
thromboprophylaxiswith nadroparin. Emergency coronary angiography revealed total occlusion of the right cor-
onary artery by a thrombus which was successfully removed by aspiration.
© 2015 The Society of Cardiovascular Academy. Production and hosting by Elsevier B.V. All rights reserved. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Testicular cancer is the most common solid tumor among young
men aged 15 to 35 years.1 Two histologic groups of testicular cancer,
seminoma and non-seminoma, have been deﬁned. Seminomas are gen-
erally treatedwith surgical resection, followed by radiotherapy for early
stage disease and chemotherapy for advanced stage disease. In contrast,
non-seminomas do not respondwell to radiotherapy and are frequently
treated with chemotherapy. Combination therapy with bleomycin,
etoposide, and cisplatin (BEP) has been the standardﬁrst-line treatment
for testicular metastatic disease.2,3 However, BEP combination therapy
carries risk of complications itself including nephrotoxicity, ototoxicity,
neurotoxicity, secondary leukemia, therapy-related solid tumors,
infertility, pulmonary toxicity and vascular toxicity.2,3
Deep vein thrombosis, pulmonary embolism, coronary artery throm-
bosis (myocardial infraction), cerebral artery thrombosis/embolism
(stroke) and peripheral arterial thrombosis/embolism are the major
vascular complications of chemotherapy for testicular cancer.4,5
Thromboprophylaxis with lowmolecular weight heparin (LMWH) during
chemotherapy has demonstrated to give substantial risk reduction ofsearch Hospital, Department of
an).
diovascular Academy.
y. Production and hosting by Elsevthromboembolic events without a signiﬁcantly increased risk of bleeding
events.6,7 Recently, it is shown that nadroparin signiﬁcantly reduces the in-
cidence of thromboembolic events in ambulatory patients withmetastatic
or locally advanced cancer who are receiving chemotherapy.8,9
Wepresent a case of acute inferiormyocardial infraction (MI) during
the combined chemotherapy with BEP for testicular cancer under
thromboprophylaxis with nadroparin.
Case report
A 28-year-old man was transferred to the emergency unit with
sudden onset of chest pain and dyspnea during the course of BEP
chemotherapy in the Urologic Oncology Clinic. Testicular cancer (non-
seminomatous germ cell tumor) was diagnosed 2 months previously,
and surgical resection of the testis was performed. Chemotherapy
with a combination of cisplatin, etoposide, and bleomycin was started
30 days after surgery. The 5-day regimen consisted of 20mg/m2 cisplat-
in and 100 mg/m2 etoposide on days 1 and 5, and 30,000 IU bleomycin
on days 1, 8, and 15 of each course. The chemotherapywould be repeat-
ed every 21 days, maximum 4 cycles. Subcutaneous injections of
nadroparin (3800 IU anti-Xa, once a day) for thromboprophylaxis
were started on the ﬁrst day of the regimen.
During the third course of the chemotherapy (bleomycin infusion),
severe chest pain and dyspnea started at rest. His previous medical his-
torywas unremarkable. He did not have anymajor coronary risk factors.ier B.V. All rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 2. Aftermath of thrombus aspiration.
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There were no signiﬁcant pathologic ﬁndings in the rest of the physical
examination. The electrocardiography showed sinus rhythm and there
was an ST elevation of 3 to 4 mm at D2, D3, and AVF. In the analysis,
the following data were observed: creatine kinase 341 U/L, CK-MB
52 U/L, troponin I 1.33 ng/mL. Urgent coronary intervention was
planned for the patient. Thrombosis near to total was observed at cor-
onary angiography (Fig. 1). Thrombus aspiration was performed by in-
tervention (Fig. 2). A bare metal stent of 4.5 × 12mmwas implanted to
the proximal RCA because of the suspicion dissection at the culprit re-
gion (Fig. 3). The coronary ﬂow was TIMI-3 (Fig. 4) and chest pain
was improved immediately after stent implantation within 2 h of
chest discomfort. The patient was followed up at the ICU and was
given GP IIb/IIIa inhibitor (tiroﬁban). Echocardiography (5 h after pri-
mary PCI) revealed mild hypokinesis at the inferior wall, EF 55%, heart
chambers with normal size, and mild degree mitral regurgitation. The
patient whose general condition was ﬁne was discharged with
the treatment of clopidogrel 75 mg/day, aspirin 300 mg/day, ramipril
5 mg/day, metoprolol 25 mg/day and pravastatin 40 mg/day. The
genetic risk of hypercoagulability of the patientwas investigated. Factor
V Leiden, prothrombin, factor XIII, ﬁbrinogen, and methylenetetrahy-
drofolate reductase genes were normal. The chemotherapy regimen
was stopped after the acute MI by the oncologist. The patient was
asymptomatic at the 3rd, 6th and 12th month controls.
Discussion
We report a case of acuteMI in a patient with testicular cancer during
treatment with cisplatin-based combination chemotherapy under
nadroparin thromboprophylaxis. This complication is rare and canbe suc-
cessfully treated with classical percutaneous coronary intervention tech-
niques. There are numerous chemotherapy complicated acute MI cases
reported in the literature. Most of the cases reported to date have used
cisplatin in combination with other chemotherapeutic agents. A study
wasdemonstrated that the estimated incidence ofMI andof all cardiovas-
cular events during chemotherapy is 0.24% and 0.30% in patientswith tes-
ticular cancer.5 Twenty cisplatin based chemotherapy complicated acute
MI cases were presented in this retrospective study, but data regarding
thromboprophylaxis was not given.5 To the best of our knowledge,
acute MI during the cisplatin based combination therapy under LMWH
thromboprophylaxis has not been reported so far in the literature.
Cancer patients are at increased risk of thrombosis. Thromboembolic
event prevalence varies between 4% and 20% in cancer patients and it
was found up to 50% of cancer patients in autopsy series.9 Cancer chemo-
therapy has been shown to both amplify the prothrombotic effect of can-
cer cells and to damage vessel walls directly, and is recognized as a risk
factor for thromboembolic complications. Cisplatin is one of the most
culprit chemotherapeutic leading thromboembolic complications.8
Apart from nephrotoxicity, myelosuppressant effect, peripheral neurop-
athy and ocular toxicity, cisplatin has vascular side effects such as MI,Fig. 1. Intense thrombosis lesion at RCA coronary.cerebrovascular accident, peripheral arterial occlusion, deep vein throm-
bosis and pulmonary embolization.5 But the exact mechanism of this is
unclear. However, patients with an arterial event have elevated levels
of von Willebrand factor, t-PA, platelets, and ﬁbrinogen at baseline
and these increase further with chemotherapy. It is assumed that
thromboprophylaxis/ anticoagulation may prevent these thromboem-
bolic events and improve survival in patients with cancer through an
antitumor effect.10
The role of thromboprophylaxis in patients undergoing cisplatin-
based chemotherapy is controversial. Established guidelines recom-
mend prophylactic anticoagulation only for oncology patients in high-
risk settings, such as hospitalization, major surgery, or postoperatively.
Data on primary prevention of thrombosis in ambulatory patients
with cancer receiving chemotherapy are limited with mixed results.
Recently, a clinical trial (Prophylaxis of Thromboembolism during Che-
motherapy Trial, PROTECT) in 1150 patients on prophylactic use of
LMWH during chemotherapy reported a signiﬁcant decrease of TE in
the group receiving nadroparin comparing to placebo (2.0% vs. 3.9%).8
Although the randomized PROTECT has shown beneﬁt of primary pre-
vention with cisplatin-based combination chemotherapy in metastatic
gastrointestinal or testicular cancers,8 the TOPIC I and II trials have failed
to show any beneﬁt.11 Amore recently published Cochrane review eval-
uated the efﬁcacy and safety of parenteral anticoagulants in ambulatory
patients with cancer undergoing chemotherapy, hormonal therapy or
radiotherapy, who had no standard therapeutic or prophylactic indica-
tion for anticoagulation.12 This study investigated the effect of heparin
(either unfractionated heparin or low molecular weight heparin)
thromboprophylaxis on all-cause mortality, symptomatic venousFig. 3. 4.5 × 12 mm BMS implantation to RCA proximal.
Fig. 4. Angiogram after stent implantation.
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pulmonary embolism, arterial thrombosis (e.g. stroke, myocardial in-
farction), major bleeding, minor bleeding and quality of life.12 It was
found that heparin thromboprophylaxis may have a small effect on
mortality at 12–24 months, and is associated with decreased venous
thromboembolism risk and a likely increased minor bleeding risk, but
has no effect on arterial thrombosis.12
In literature, most MI cases related with cytostatic treatment have
thrombus formation, indicating that coronary accidents in these
patients are triggered by a thrombotic cascade rather than an athero-
sclerotic process. Most of the patients have had no risk factors for car-
diovascular diseases. Similar to the other published cases, this patient
had no risk factors related to coronary artery disease. Also, he had no
risk factor for thrombophilia. Other drugs related to thrombosis in our
case are etoposide and bleomycin. MI has been reportedwith etoposide
treatment.13
Karabay et al., presented a case with cisplatin-induced multiple cor-
onary thrombi. They treated the patient with stenting and tiroﬁban.
They speculate that in the absence of intravascular ultrasound to ex-
clude the presence of coronary atherosclerosis, stents can be used and
tiroﬁban might decrease or even eliminate the thrombus.14
Considering the rarity of arterial thrombotic complication in ambula-
tory patients with testicular cancer following cisplatin based chemo-
therapy, the routine use of prophylactic anticoagulation is not
currently recommended in this setting. Arterial thrombotic complica-
tion can occur in patients with and without coronary artery disease
risk factors. Susceptible patients should be identiﬁed andmaybe treated
withmore effective doses of anticoagulation (example, standard dose of
LMWH for treatment of thrombosis, instead of thromboprophylaxis
dose). Also, risk of bleeding should be calculated before treatment
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